Talaris Therapeutics, Inc. operates as a late-clinical stage cell therapy company in the United States. The company engages in developing a method of allogeneic hematopoietic stem cell transplantation to transform the standard of care in solid organ transplantation and severe autoimmune diseases, as well as severe non-malignant blood, immune, and metabolic disorders. Its lead product candidate is FCR001, a novel allogeneic cell therapy that is in Phase II trial for living donor kidney transplant patients. The company is also developing FCR002 in deceased donor kidney transplants; FCR001 in patients with a severe form of scleroderma; and FCR001 for one or more severe non-malignant blood, immune, or metabolic disorders. Talaris Therapeutics, Inc. was founded in 1988 and is headquartered in Louisville, Kentucky.
IPO Year: 2021
Exchange: NASDAQ
Website: talaristx.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/20/2022 | $18.00 | Buy | H.C. Wainwright |
| 7/5/2022 | $20.00 → $8.00 | Overweight → Equal-Weight | Morgan Stanley |
| 11/12/2021 | $21.00 → $22.00 | Outperform | SVB Leerink |